{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:42Z","timestamp":1787836962104,"version":"build-2784847793"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cancer Council NSW Project Grants","award":["RG 23-04 and RG 25-13"],"award-info":[{"award-number":["RG 23-04 and RG 25-13"]}]},{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"crossref","award":["C-PJ-126-Exper-2019 and 2022-CP-IDMH-019"],"award-info":[{"award-number":["C-PJ-126-Exper-2019 and 2022-CP-IDMH-019"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100022217","name":"Flinders Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022217","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"crossref","award":["2020_PdCCRS_2001432 and 2023_PCRS_0269"],"award-info":[{"award-number":["2020_PdCCRS_2001432 and 2023_PCRS_0269"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2047980"],"award-info":[{"award-number":["2047980"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Changzhou Qianhong Biopharmaceuticals Co. Ltd., Changzhou LeSun Pharmaceuticals Ltd."},{"name":"Aucentra Therapeutics Pty. Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>CDK4-selective inhibitors are emerging as promising anticancer agents. Relative to dual CDK4\/6 inhibitors, CDK4-selective inhibitors have the potential to retain efficacy while improving tolerability. However, the therapeutic value and mechanistic consequences of selectively targeting CDK4 in prostate cancer remain largely undefined. Here, we investigated the anti-tumour activity and mode of action of the CDK4 inhibitors AU2-94 and atirmociclib across diverse prostate cancer models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Antiproliferative activity was assessed in a panel of AR-driven and AR-independent prostate cancer cell lines spanning hormone-sensitive and castration-resistant states. Efficacy was further evaluated in organoids derived from patient-derived xenografts and in xenograft mouse models. Biochemical and molecular analyses were performed to evaluate CDK4 selectivity, RB pathway engagement, transcriptional reprogramming, and downstream effects on cell-cycle regulation, and resistance-associated programmes. AU2-94 was also tested in combination with standard-of-care therapies (enzalutamide and docetaxel) and the PI3K inhibitor alpelisib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AU2-94 exhibited greater selectivity for CDK4 compared with atirmociclib. AU2-94 suppressed proliferation across prostate cancer models irrespective of AR status and retained activity in aggressive and therapy-resistant settings. In RB-proficient in vitro models, AU2-94 reduced RB phosphorylation, attenuated E2F1-dependent transcriptional outputs, activated AR signalling, and decreased expression of proliferation-associated factors such as FOXM1. In vivo, AU2-94 inhibited the growth of both AR-driven (LNCaP) and AR-independent (PC3) xenografts and suppressed RB pathway signalling. Moreover, AU2-94 demonstrated additive or synergistic effects when combined with enzalutamide, docetaxel, or alpelisib that were associated with reinforced cell-cycle blockade and suppression of resistance-associated signalling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings establish selective CDK4 inhibition as a therapeutically active and mechanistically rational strategy in prostate cancer and support AU2-94 as a candidate for further preclinical and clinical development, including in combination regimens for advanced and therapy-resistant disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03763-x","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:34:13Z","timestamp":1781710453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Ava","family":"Safaroghli-azar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laychiluh B.","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimma","family":"Lenjisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Dickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj K.","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samyukta","family":"Sita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita K.C.","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell G.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"Selth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-5525","authenticated-orcid":false,"given":"Shudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"2","key":"3763_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol. 2023;84(2):191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021.","journal-title":"Eur Urol"},{"issue":"2","key":"3763_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63\u201389. https:\/\/doi.org\/10.14740\/wjon1191.","journal-title":"World J Oncol"},{"key":"3763_CR3","doi-asserted-by":"publisher","unstructured":"Messner EA, Steele TM, Tsamouri MM, Hejazi N, Gao AC, Mudryj M, et al. The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy. Biomedicines. 2020;8(10). https:\/\/doi.org\/10.3390\/biomedicines8100422.","DOI":"10.3390\/biomedicines8100422"},{"issue":"1","key":"3763_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"MH Tan","year":"2015","unstructured":"Tan MH, Li J, Xu HE, Melcher K, Yong EL. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 2015;36(1):3\u201323. https:\/\/doi.org\/10.1038\/aps.2014.18.","journal-title":"Acta Pharmacol Sin"},{"issue":"11","key":"3763_CR5","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s11912-024-01614-6","volume":"26","author":"MNE Almeeri","year":"2024","unstructured":"Almeeri MNE, Awies M, Constantinou C. Prostate Cancer, Pathophysiology and Recent Developments in Management: A Narrative Review. Curr Oncol Rep. 2024;26(11):1511\u20139. https:\/\/doi.org\/10.1007\/s11912-024-01614-6.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"3763_CR6","doi-asserted-by":"publisher","first-page":"T179","DOI":"10.1530\/erc-16-0422","volume":"23","author":"I Coutinho","year":"2016","unstructured":"Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer. 2016;23(12):T179\u201397. https:\/\/doi.org\/10.1530\/erc-16-0422.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"3763_CR7","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1530\/erc-19-0420","volume":"27","author":"A Davies","year":"2020","unstructured":"Davies A, Zoubeidi A, Selth LA. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. Endocr Relat Cancer. 2020;27(2):R35\u201350. https:\/\/doi.org\/10.1530\/erc-19-0420.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"3763_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-023-00444-9","volume":"12","author":"GL Varaprasad","year":"2023","unstructured":"Varaprasad GL, Gupta VK, Prasad K, Kim E, Tej MB, Mohanty P, et al. Recent advances and future perspectives in the therapeutics of prostate cancer. Exp Hematol Oncol. 2023;12(1):80. https:\/\/doi.org\/10.1186\/s40164-023-00444-9.","journal-title":"Exp Hematol Oncol"},{"issue":"21","key":"3763_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618.","journal-title":"N Engl J Med"},{"issue":"5","key":"3763_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1517\/14656566.2013.775251","volume":"14","author":"SK Pal","year":"2013","unstructured":"Pal SK, Stein CA, Sartor O. Enzalutamide for the treatment of prostate cancer. Expert Opin Pharmacother. 2013;14(5):679\u201385. https:\/\/doi.org\/10.1517\/14656566.2013.775251.","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"3763_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396. https:\/\/doi.org\/10.6004\/jnccn.2023.0050.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"3763_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/1541-7786.Mcr-16-0236","volume":"15","author":"Y Zhan","year":"2017","unstructured":"Zhan Y, Zhang G, Wang X, Qi Y, Bai S, Li D, et al. Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance. Mol Cancer Res. 2017;15(1):59\u201368. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-16-0236.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"3763_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","volume":"37","author":"K Fujita","year":"2019","unstructured":"Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Mens Health. 2019;37(3):288\u201395. https:\/\/doi.org\/10.5534\/wjmh.180040.","journal-title":"World J Mens Health"},{"key":"3763_CR14","doi-asserted-by":"publisher","unstructured":"Siskin M, Economides MP, Wise DR. Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future. Cancers (Basel). 2025;17(5). https:\/\/doi.org\/10.3390\/cancers17050774.","DOI":"10.3390\/cancers17050774"},{"issue":"20","key":"3763_CR15","first-page":"4511","volume":"57","author":"S Lu","year":"1997","unstructured":"Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 1997;57(20):4511\u20136.","journal-title":"Cancer Res"},{"issue":"5","key":"3763_CR16","first-page":"1891","volume":"6","author":"M Drobnjak","year":"2000","unstructured":"Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000;6(5):1891\u20135.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3763_CR17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/sj.bjc.6603615","volume":"96","author":"C Comstock","year":"2007","unstructured":"Comstock C, Revelo M, Buncher C, Knudsen K. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer. 2007;96(6):970\u20139.","journal-title":"Br J Cancer"},{"issue":"5","key":"3763_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1365-2559.2011.03800.x","volume":"58","author":"A Fleischmann","year":"2011","unstructured":"Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High\u2010level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology. 2011;58(5):781\u20139.","journal-title":"Histopathology"},{"issue":"6","key":"3763_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/cncr.31161","volume":"124","author":"SK Pal","year":"2018","unstructured":"Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, et al. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). Cancer. 2018;124(6):1216\u201324.","journal-title":"Cancer"},{"key":"3763_CR20","doi-asserted-by":"publisher","unstructured":"Safaroghli-azar A, Mekonnen LB, Lenjisa J, Milne R, Wang S. Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors. J Hematol Oncol. 2026;19(1):31. https:\/\/doi.org\/10.1186\/s13045-026-01794-7.","DOI":"10.1186\/s13045-026-01794-7"},{"key":"3763_CR21","doi-asserted-by":"publisher","unstructured":"Kase AM, Copland JA III, Tan W. Novel therapeutic strategies for CDK4\/6 inhibitors in metastatic castrate-resistant prostate cancer. OncoTargets therapy. 2020;13:10499\u2013513. https:\/\/doi.org\/10.2147\/OTT.S266085.","DOI":"10.2147\/OTT.S266085"},{"issue":"11","key":"3763_CR22","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","volume":"27","author":"PL Palmbos","year":"2021","unstructured":"Palmbos PL, Daignault-Newton S, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, et al. A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer. Clin Cancer Res. 2021;27(11):3017\u201327.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3763_CR23","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1158\/1078-0432.CCR-21-4302","volume":"28","author":"I De Kouchkovsky","year":"2022","unstructured":"De Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, et al. A phase Ib\/II study of the CDK4\/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2022;28(8):1531\u20139.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3763_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1158\/1541-7786.MCR-17-0028","volume":"15","author":"JP Stice","year":"2017","unstructured":"Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, et al. CDK4\/6 therapeutic intervention and viable alternative to taxanes in CRPC. Mol Cancer Res. 2017;15(6):660\u20139.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"3763_CR25","first-page":"90","volume":"125","author":"R Scheicher","year":"2015","unstructured":"Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan A-S, Prchal-Murphy M, Heller G, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood J Am Soc Hematol. 2015;125(1):90\u2013101.","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"3763_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2004.08.002","volume":"118","author":"M Malumbres","year":"2004","unstructured":"Malumbres M, Sotillo Ro, Santamar\u0131\u0301a D, Gal\u00e1n J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;118(4):493\u2013504.","journal-title":"Cell"},{"issue":"3","key":"3763_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ygyno.2020.09.012","volume":"159","author":"L Bantie","year":"2020","unstructured":"Bantie L, Tadesse S, Likisa J, Yu M, Noll B, Heinemann G, et al. A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer. Gynecol Oncol. 2020;159(3):827\u201338.","journal-title":"Gynecol Oncol"},{"issue":"6Supplement","key":"3763_CR28","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1538-7445.AM2024-5701","volume":"84","author":"L Bantie","year":"2024","unstructured":"Bantie L, Likisa J, Rahaman M, Teo T, Safaroghliazar A, Basnet SK, et al. AU2-94: A CDK4-specific inhibitor with the marked anti-tumor efficacy. Cancer Res. 2024;84(6Supplement):5701.","journal-title":"Cancer Res"},{"key":"3763_CR29","doi-asserted-by":"crossref","unstructured":"Safaroghli-Azar A, Mekonnen LB, Hassankhani R, Lenjisa J, Basnet SK, Batayneh H et al. A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. Investig New Drugs. 2025:1\u201314.","DOI":"10.1007\/s10637-025-01550-7"},{"issue":"3","key":"3763_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2025.02.006","volume":"43","author":"CL Palmer","year":"2025","unstructured":"Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S, et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell. 2025;43(3):464\u201381.e14.","journal-title":"Cancer Cell"},{"key":"3763_CR31","doi-asserted-by":"crossref","unstructured":"Zhu H, Sun H, Xu W, Li J, Liu X, Zhang T et al. Abstract P4-10-06: Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+ HER2-breast cancer models. Clinical Cancer Research. 2025;31(12_Supplement):P4-10-06-P4-10-06.","DOI":"10.1158\/1557-3265.SABCS24-P4-10-06"},{"issue":"12","key":"3763_CR32","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/bph.13974","volume":"175","author":"S Tadesse","year":"2018","unstructured":"Tadesse S, Bantie L, Tomusange K, Yu M, Islam S, Bykovska N, et al. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents. Br J Pharmacol. 2018;175(12):2399\u2013413.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"3763_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.Cd-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, et al. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discov. 2017;7(1):54\u201371. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-1263.","journal-title":"Cancer Discov"},{"issue":"2","key":"3763_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"issue":"suppl2","key":"3763_CR35","doi-asserted-by":"publisher","first-page":"W441","DOI":"10.1093\/nar\/gkp253","volume":"37","author":"RZ Cer","year":"2009","unstructured":"Cer RZ, Mudunuri U, Stephens R, Lebeda FJ. IC 50-to-K i: a web-based tool for converting IC 50 to K i values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res. 2009;37(suppl2):W441\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"3763_CR36","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1021\/acs.jmedchem.6b01670","volume":"60","author":"S Tadesse","year":"2017","unstructured":"Tadesse S, Yu M, Mekonnen LB, Lam F, Islam S, Tomusange K, et al. Highly potent, selective, and orally bioavailable 4-thiazol-N-(pyridin-2-yl) pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation. J Med Chem. 2017;60(5):1892\u2013915.","journal-title":"J Med Chem"},{"issue":"4","key":"3763_CR37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"The Molecular Taxonomy of Primary Prostate Cancer","year":"2015","unstructured":"The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163(4):1011\u201325. https:\/\/doi.org\/10.1016\/j.cell.2015.10.025.","journal-title":"Cell"},{"issue":"5","key":"3763_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.Cd-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0095.","journal-title":"Cancer Discov"},{"issue":"7406","key":"3763_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239\u201343. https:\/\/doi.org\/10.1038\/nature11125.","journal-title":"Nature"},{"issue":"1","key":"3763_CR40","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1038\/s41467-018-06916-5","volume":"9","author":"JM McFarland","year":"2018","unstructured":"McFarland JM, Ho ZV, Kugener G, Dempster JM, Montgomery PG, Bryan JG, et al. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun. 2018;9(1):4610.","journal-title":"Nat Commun"},{"issue":"3","key":"3763_CR41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276\u20138.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3763_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635.","journal-title":"Bioinformatics"},{"issue":"12","key":"3763_CR43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"issue":"43","key":"3763_CR44","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3763_CR45","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2(3):100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.","journal-title":"Innov (Camb)"},{"issue":"6","key":"3763_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"issue":"4","key":"3763_CR47","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell. 2017;32(4):474\u2013e896. https:\/\/doi.org\/10.1016\/j.ccell.2017.09.003.","journal-title":"Cancer Cell"},{"issue":"22","key":"3763_CR48","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1158\/1078-0432.Ccr-19-1587","volume":"25","author":"DE Spratt","year":"2019","unstructured":"Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, et al. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Na\u00efve Primary Prostate Cancer. Clin Cancer Res. 2019;25(22):6721\u201330. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1587.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3763_CR49","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1038\/s41467-021-25175-5","volume":"12","author":"GP Risbridger","year":"2021","unstructured":"Risbridger GP, Clark AK, Porter LH, Toivanen R, Bakshi A, Lister NL, et al. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat Commun. 2021;12(1):5049. https:\/\/doi.org\/10.1038\/s41467-021-25175-5.","journal-title":"Nat Commun"},{"issue":"1","key":"3763_CR50","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","volume":"159","author":"D Gao","year":"2014","unstructured":"Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176\u201387. https:\/\/doi.org\/10.1016\/j.cell.2014.08.016.","journal-title":"Cell"},{"issue":"5","key":"3763_CR51","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.eururo.2018.06.020","volume":"74","author":"MG Lawrence","year":"2018","unstructured":"Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, et al. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. Eur Urol. 2018;74(5):562\u201372. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.020.","journal-title":"Eur Urol"},{"issue":"17","key":"3763_CR52","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1158\/1078-0432.Ccr-18-0409","volume":"24","author":"ML Beshiri","year":"2018","unstructured":"Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, et al. A PDX\/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res. 2018;24(17):4332\u201345. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0409.","journal-title":"Clin Cancer Res"},{"issue":"42","key":"3763_CR53","doi-asserted-by":"publisher","first-page":"e2509222122","DOI":"10.1073\/pnas.2509222122","volume":"122","author":"J Xie","year":"2025","unstructured":"Xie J, Shen K, Liang W, Kuang Z, Shrestha RK, Hanson AR, et al. Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival. Proc Natl Acad Sci U S A. 2025;122(42):e2509222122. https:\/\/doi.org\/10.1073\/pnas.2509222122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12Supplement","key":"3763_CR54","doi-asserted-by":"publisher","first-page":"LB137","DOI":"10.1158\/1538-7445.AM2022-LB137","volume":"82","author":"K Medley","year":"2022","unstructured":"Medley K, Li Z, Vankayalapati S, Paritala S, Yan D, Coffman K, et al. Abstract LB137: Orally available, CDK9 selective, small molecule inhibitors shows promise in n-Myc-driven neuroendocrine prostate cancers (NEPC). Cancer Res. 2022;82(12Supplement):LB137\u2013LB.","journal-title":"Cancer Res"},{"key":"3763_CR55","doi-asserted-by":"crossref","unstructured":"Corona SP, Generali D. Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HER2\u2009\u2013\u2009advanced breast cancer. Drug design, development and therapy. 2018:321\u2009\u2013\u200930.","DOI":"10.2147\/DDDT.S137783"},{"issue":"3","key":"3763_CR56","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","volume":"21","author":"CE Onesti","year":"2021","unstructured":"Onesti CE, Jerusalem G. CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticancer Ther. 2021;21(3):283\u201398. https:\/\/doi.org\/10.1080\/14737140.2021.1852934.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"3763_CR57","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ccr.2011.10.001","volume":"20","author":"L Anders","year":"2011","unstructured":"Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, et al. A systematic screen for CDK4\/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011;20(5):620\u201334.","journal-title":"Cancer Cell"},{"issue":"1","key":"3763_CR58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0014-5793(01)02915-5","volume":"507","author":"TW Leung","year":"2001","unstructured":"Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY, et al. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett. 2001;507(1):59\u201366.","journal-title":"FEBS Lett"},{"key":"3763_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv468","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J. Nucleic Acids Res. 2015;43(W1):W566\u201370. https:\/\/doi.org\/10.1093\/nar\/gkv468. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap."},{"issue":"13","key":"3763_CR60","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397.","journal-title":"N Engl J Med"},{"issue":"4","key":"3763_CR61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eururo.2016.03.017","volume":"70","author":"CP Evans","year":"2016","unstructured":"Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, et al. The PREVAIL study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naive metastatic castration-resistant prostate cancer. Eur Urol. 2016;70(4):675\u201383.","journal-title":"Eur Urol"},{"issue":"5","key":"3763_CR62","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575\u201386. https:\/\/doi.org\/10.1016\/j.ccr.2011.04.008.","journal-title":"Cancer Cell"},{"issue":"7","key":"3763_CR63","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/1535-7163.Mct-19-0936","volume":"19","author":"R Adelaiye-Ogala","year":"2020","unstructured":"Adelaiye-Ogala R, Gryder BE, Nguyen YTM, Alilin AN, Grayson AR, Bajwa W, et al. Targeting the PI3K\/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor. Mol Cancer Ther. 2020;19(7):1436\u201347. https:\/\/doi.org\/10.1158\/1535-7163.Mct-19-0936.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"3763_CR64","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/1535-7163.Mct-11-0289","volume":"11","author":"M Mar\u00edn-Aguilera","year":"2012","unstructured":"Mar\u00edn-Aguilera M, Codony-Servat J, Kalko SG, Fern\u00e1ndez PL, Bermudo R, Buxo E, et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther. 2012;11(2):329\u201339. https:\/\/doi.org\/10.1158\/1535-7163.Mct-11-0289.","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"3763_CR65","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/jco.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534\u201340. https:\/\/doi.org\/10.1200\/jco.2011.39.4767.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3763_CR66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cncr.23195","volume":"112","author":"RW Ross","year":"2008","unstructured":"Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112(3):521\u20136. https:\/\/doi.org\/10.1002\/cncr.23195.","journal-title":"Cancer"},{"issue":"1","key":"3763_CR67","doi-asserted-by":"publisher","first-page":"13014","DOI":"10.1038\/s41598-019-49484-4","volume":"9","author":"D Cretella","year":"2019","unstructured":"Cretella D, Fumarola C, Bonelli M, Alfieri R, La Monica S, Digiacomo G, et al. Pre-treatment with the CDK4\/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Sci Rep. 2019;9(1):13014. https:\/\/doi.org\/10.1038\/s41598-019-49484-4.","journal-title":"Sci Rep"},{"issue":"7","key":"3763_CR68","doi-asserted-by":"publisher","first-page":"597","DOI":"10.4161\/cbt.24592","volume":"14","author":"XH Zhang","year":"2013","unstructured":"Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH. A CDK4\/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. Cancer Biol Ther. 2013;14(7):597\u2013605. https:\/\/doi.org\/10.4161\/cbt.24592.","journal-title":"Cancer Biol Ther"},{"issue":"14","key":"3763_CR69","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1073\/pnas.0501203102","volume":"102","author":"JT Lim","year":"2005","unstructured":"Lim JT, Mansukhani M, Weinstein IB. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci U S A. 2005;102(14):5156\u201361. https:\/\/doi.org\/10.1073\/pnas.0501203102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3763_CR70","doi-asserted-by":"crossref","unstructured":"Tewari AK, Cheung AT, Crowdis J, Conway JR, Camp SY, Wankowicz SA et al. Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Rep. 2021;36(10):109665.","DOI":"10.1016\/j.celrep.2021.109665"},{"issue":"1","key":"3763_CR71","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s43018-020-00135-y","volume":"2","author":"AC Watt","year":"2021","unstructured":"Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EY, Qiu X, et al. CDK4\/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat Cancer. 2021;2(1):34\u201348.","journal-title":"Nat cancer"},{"issue":"1","key":"3763_CR72","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1038\/s41467-023-39613-z","volume":"14","author":"EF Schuster","year":"2023","unstructured":"Schuster EF, Lopez-Knowles E, Alataki A, Zabaglo L, Folkerd E, Evans D, et al. Molecular profiling of aromatase inhibitor sensitive and resistant ER+ HER2-postmenopausal breast cancers. Nat Commun. 2023;14(1):4017.","journal-title":"Nat Commun"},{"issue":"5","key":"3763_CR73","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1074\/jbc.M114.607846","volume":"290","author":"SH Lee","year":"2015","unstructured":"Lee SH, Johnson D, Luong R, Sun Z. Crosstalking between androgen and PI3K\/AKT signaling pathways in prostate cancer cells. J Biol Chem. 2015;290(5):2759\u201368. https:\/\/doi.org\/10.1074\/jbc.M114.607846.","journal-title":"J Biol Chem"},{"issue":"5","key":"3763_CR74","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1158\/1541-7786.Mcr-21-0322","volume":"20","author":"X Gao","year":"2022","unstructured":"Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, et al. Blocking PI3K p110\u03b2 Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022;20(5):673\u201385. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-21-0322.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"3763_CR75","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1038\/s41467-021-25341-9","volume":"12","author":"N Mao","year":"2021","unstructured":"Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, et al. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nat Commun. 2021;12(1):5053.","journal-title":"Nat Commun"},{"issue":"1","key":"3763_CR76","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11523-016-0453-6","volume":"12","author":"CM Statz","year":"2017","unstructured":"Statz CM, Patterson SE, Mockus SM. mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review. Target Oncol. 2017;12(1):47\u201359. https:\/\/doi.org\/10.1007\/s11523-016-0453-6.","journal-title":"Target Oncol"},{"issue":"2","key":"3763_CR77","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonz\u00e1lez-Bar\u00f3n M. PI3K\/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193\u2013204. https:\/\/doi.org\/10.1016\/j.ctrv.2003.07.007.","journal-title":"Cancer Treat Rev"},{"key":"3763_CR78","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2017.02.030","volume":"81","author":"AJ Armstrong","year":"2017","unstructured":"Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, et al. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. Eur J Cancer. 2017;81:228\u201336. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.030.","journal-title":"Eur J Cancer"},{"issue":"21","key":"3763_CR79","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1038\/s41388-019-0708-7","volume":"38","author":"J Cao","year":"2019","unstructured":"Cao J, Zhu Z, Wang H, Nichols TC, Lui GYL, Deng S, et al. Combining CDK4\/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. Oncogene. 2019;38(21):4125\u201341. https:\/\/doi.org\/10.1038\/s41388-019-0708-7.","journal-title":"Oncogene"},{"issue":"11","key":"3763_CR80","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-23-3436","volume":"30","author":"N Agarwal","year":"2024","unstructured":"Agarwal N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, Colomba E, Gravis G, et al. A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration\u2013Resistant Prostate Cancer: Results from CYCLONE 1. Clin Cancer Res. 2024;30(11):2377\u201383.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03763-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:02:43Z","timestamp":1787835763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03763-x","relation":{"references":[{"id-type":"doi","id":"10.1093\/nar\/gkv468","asserted-by":"subject"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not involve human participants, patient data, or human tissue samples. All animal procedures were approved by the University of South Australia Animal Ethics Committee (Ethics Approval Numbers: U12-23 and U33-22) and conducted in accordance with institutional guidelines for the care and use of laboratory animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have read and approved the final manuscript and consent to its publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. W. is founder of Aucentra Therapeutics Pty. Ltd., and Changzhou LeSun Pharmaceuticals Ltd., as well a consultant to Changzhou Qianhong BioPharma Co. Ltd. M.G.L: research collaborations with AstraZeneca and Pfizer. No potential conflicts of interests were disclosed by the other authors.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"188"}}